Need Assistance?

  • US & Canada:
  • UK: +
* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Substrate for carboxypeptidase Y.

Functional Peptides
Catalog number
CAS number
Molecular Formula
Molecular Weight
Z-L-alanyl-L-phenylalanine; N-Carbobenzoxy-L-alanyl-L-phenylalanine; (S)-2-((S)-2-(benzyloxycarbonylamino)propanamido)-3-phenylpropanoic acid; Z Ala Phe OH
White powder
≥ 98% (HPLC)
1.253 g/cm3
Boiling Point
643.7°C at 760 mmHg
Store at 2-8 °C
1. Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors
Maciej Purwin, Agnieszka Markowska, Irena Bruzgo, Tomasz Rusak, Arkadiusz Surażyński, Urszula Jaworowska, Krystyna Midura-Nowaczek Int J Pept Res Ther. 2017;23(2):235-245. doi: 10.1007/s10989-016-9555-3. Epub 2016 Sep 19.
Fifteen new peptide derivatives of ɛ-aminocaproic acid (EACA) containing the known fragment -Ala-Phe-Lys- with an affinity for plasmin were synthesised in the present study. The synthesis was carried out a solid phase. The following compounds were synthesised: H-Phe-Lys-EACA-X, H-d-Ala-Phe-Lys-EACA-X, H-Ala-Phe-Lys-EACA-X, H-d-Ala-Phe-EACA-X and H-Ala-Phe-EACA-X, where X = OH, NH2 and NH-(CH2)5-NH2. All peptides, except for those containing the sequence H-Ala-Phe-EACA-X, displayed higher inhibitory activity against plasmin than EACA. The most active and selective inhibitor of plasmin was the compound H-d-Ala-Phe-Lys-EACA-NH2 which inhibited the amidolytic activity of plasmin (IC50 = 0.02 mM), with the antifibrinolytic activity weaker than EACA. The resulting peptides did not affect the viability of fibroblast cells, colon cancer cell line DLD-1, breast MCF-7 and MDA-MB-231 cell lines.
2. Transport characteristics of peptides and peptidomimetics: I. N-methylated peptides as substrates for the oligopeptide transporter and P-glycoprotein in the intestinal mucosa
J Gao, M Sudoh, J Aubé, R T Borchardt J Pept Res. 2001 Apr;57(4):316-29. doi: 10.1046/j.1397-002x.2001.00000.x.
Peptides and peptidomimetics often exhibit poor oral bioavailability due to their metabolic instability and low permeation across the intestinal mucosa. N-Methylation has been used successfully in peptide-based drug design in an attempt to improve the metabolic stability of a peptide-based lead compound. However, the effect of N-methylation on the absorption of peptides through the intestinal mucosa is not well understood, particularly when transporters, i.e. the oligopeptide transporter (OPT) and P-glycoprotein (P-gp), modulate the passive diffusion of these types of molecules. To examine this, terminally free and terminally modified (N-acetylated and C-amidated) analogs of H-Ala-Phe-Ala-OH with N-methyl groups on either the Ala-Phe or Phe-Ala peptide bond were synthesized. Transport studies using Caco-2 cell monolayers, an in vitro model of the intestinal mucosa, showed that N-methylation of the Ala-Phe peptide bond of H-Ala-Phe-Ala-OH stabilized the molecule to protease degradation, and the resulting analog exhibited significant substrate activity for OPT. However, N-methylation of the Phe-Ala peptide bond of H-Ala-Phe-Ala-OH did not stabilize the molecule to protease degradation, and the substrate activity of the resulting molecule for OPT could not be determined. Interestingly, N-methylation of the Phe-Ala peptide bond of the terminally modified tripeptide Ac-Ala-Phe-Ala-NH2 decreased the substrate activity of the molecule for the efflux transporter P-gp. In contrast, N-methylation of the Ala-Phe peptide bond of the terminally modified tripeptide Ac-Ala-Phe-Ala-NH2 increased the substrate activity of the molecule for P-gp.
3. Opioid activities of D-Arg2-substituted tetrapeptides
T Sato, S Sakurada, T Sakurada, S Furuta, K Chaki, K Kisara, Y Sasaki, K Suzuki J Pharmacol Exp Ther. 1987 Aug;242(2):654-9.
The antinociceptive effects and mechanisms of action of H-Tyr-D-Ala-Phe-Gly-OH, H-Tyr-D-Arg-Phe-Gly-OH and H-Tyr-D-Arg-Phe-sarcosine(Sar)-OH have been investigated. The ED50 values of these peptides were 510.0, 8.2 and 2.0 pmol, respectively, when administered i.c.v. in the mouse tail-pressure test (dermorphin = 5.7 pmol and morphine = 1.2 nmol). These activities were remarkably potent and relatively long lasting. Their IC50 values were 676.8, 23.1 and 6.6 nM, respectively (dermorphin = 3.75 and morphine = 214.3 nM) in the guinea pig isolated ileum assay, and 138.50, 5.25 and 1.10 nM, respectively (dermorphin = 3.80 and morphine = 28.00 nM) in the radioreceptor assay utilizing [3H]naloxone as the opioid receptor ligand. In the evaluation of their inhibitory effects to enkephalin-degrading enzymes, the IC50 values of H-Tyr-D-Arg-Phe-Gly-OH, H-Tyr-D-Arg-Phe-Sar-OH and H-Tyr-D-Ala-Phe-Gly-OH were 5.4, 14.5 and more than 50.0 microM, respectively (bestatin = 0.1 microM) against aminopeptidase and 1.18, 1.40 and more than 50.0 microM, respectively (captopril = 0.38 and D-Phe-2S-, 3R-3-amino-2-hydroxy-4-phenylbutanoic acid = more than 100 microM) against the cleaving enzymes of enkephalin at its Gly3-Phe4 bond. The authors suggest that the marked antinociceptive potency of H-Tyr-D-Arg-Phe-Gly-OH and H-Tyr-D-Arg-Phe-Sar-OH is mainly due to high opioid receptor affinity. Their inhibitory effects on enkephalin-degrading enzymes and enzymatic stability also greatly contribute to their potent and long-lasting opioid activities.

Online Inquiry

Verification code
Inquiry Basket